BIO Asia–Taiwan 2025, the region’s premier and most expansive biotechnology event, officially opens its doors today at the Taipei Nangang Exhibition Center (TaiNEX 1 & 2), welcoming biotech professionals, innovators, and thought leaders from across the globe. Under this year’s forward-looking theme, “Next Wave of Biotech Opportunities”, the event sets the stage for groundbreaking innovation, strategic investment, and global collaboration in life sciences.
Spanning an unprecedented nine days across three weeks, the event has expanded significantly in scope and scale, featuring:a
850 exhibiting companies from 19 countries
Over 2,200 booths organised across 23 themed zones
More than 8,000 one-on-one partnering meetings anticipated
Participation from leading academic institutions and government agencies
Newly added dual Demo Days to accelerate innovation showcase
Powering Asia’s Biotech Ambitions
From July 23–27, BIO Asia–Taiwan 2025 will spotlight Taiwan’s robust biotech ecosystem alongside global advancements. Industry giants including Merck, FUJIFILM, Cytiva, BD, Lonza, and Charles River will be joined by regional leaders such as PharmaEssentia, Bora Pharmaceuticals, Taimed Biologics, and Formosa Laboratories to unveil the latest in biopharmaceuticals, CDMO capabilities, medtech, and regenerative therapies.
Twelve national pavilions—including from the US, Japan, Switzerland, India, Belgium, and Australia—affirm the event’s growing international draw, with representatives from over 50 countries expected to attend.
Strategic Zones: Spotlighting Innovation Across the Value Chain
This year’s exhibition features three marquee industry zones:
CDMO Zone – showcasing Taiwan’s contract manufacturing excellence with players such as EirGenix, Mycenax, and the Taiwan CDMO Alliance.
Biopharma & Medtech Zone – unveiling advances in drug discovery, diagnostics, and healthcare devices.
Cell & Regenerative Therapies Zone – highlighting breakthroughs from companies like ChainHome Biotech and Han Biomedical in cell-based therapies and regenerative solutions.
Fuel for Future Growth: Investment and Partnering
The renowned Investment Forum returns on July 23–24, with 30 high-potential companies pitching innovations ranging from oncology and cell therapy to novel drug delivery technologies. Venture capitalists and strategics will explore Taiwan’s biotech pipeline, spotlighting M&A, licensing trends, and cross-border collaboration.
Alongside, over 400 global companies from 29 countries are participating in BIO’s signature Partnering Program, with a record-breaking 8,000+ meetings forecast—underscoring the event’s pivotal role in catalysing dealmaking and R&D partnerships.
A Platform for Vision and Voice
World-class forums across five days will feature international experts such as:
George Hara, UN Ambassador and 2024 BIO Asia Award recipient, on biotech’s socioeconomic impact.
David Flores, President of BioCentury, offering incisive insights into global investment trajectories.
For the first time, Taiwan’s TAITRA will also convene the Medical Device & Health/Beauty Business Forum, opening up further frontiers for cross-industry engagement.
Academia, Policy, and Progress
Ten of Taiwan’s top universities and research institutions—including National Taiwan University, Taipei Medical University, and China Medical University—will present their latest R&D, alongside national showcases from the Ministry of Economic Affairs, Ministry of Health and Welfare, and National Health Research Institutes.
Join the Next Wave of Biotech
